Long-term survival benefit of ramipril in patients with acute myocardial infarction complicated by heart failure

  title={Long-term survival benefit of ramipril in patients with acute myocardial infarction complicated by heart failure},
  author={Jianhua Wu and Alistair S. Hall and Chris P. Gale},
  pages={389 - 395}
Aims ACE inhibition reduces mortality and morbidity in patients with heart failure after acute myocardial infarction (AMI). However, there are limited randomised data about the long-term survival benefits of ACE inhibition in this population. Methods In 1993, the Acute Infarction Ramipril Efficacy (AIRE) study randomly allocated patients with AMI and clinical heart failure to ramipril or placebo. The duration of masked trial therapy in the UK cohort (603 patients, mean age=64.7 years, 455 male… 
Long-Term Pharmacological Management of Reduced Ejection Fraction Following Acute Myocardial Infarction: Current Status and Future Prospects
This work focuses on the pharmacological management of left ventricular systolic dysfunction (LVSD) following an acute myocardial infarction, and Sacubitril-valsartan has not yet been shown to be superior to an ACE inhibitor in reducing cardiovascular mortality and HF events in patients with LVSD post MI.
Predictive Value of Blood Urea Nitrogen to Albumin Ratio in Long-Term Mortality in Intensive Care Unit Patients with Acute Myocardial Infarction: A Propensity Score Matching Analysis
A higher BAR (>7.83) was associated with four-year mortality in patients with AMI, and as an easily available biomarker, BAR can predict the long-term mortality in AMI patients independently.


Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy.
The data provide robust evidence that administration of ramipril to patients with clinically defined heart failure after acute myocardial infarction results in a survival benefit that is not only large in magnitude, but also sustained over many years.
The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction: follow-up to 12 years.
In patients with LVD, use of trandolapril shortly after an MI for 2-4 years has long-term benefits, and the beneficial effect on mortality and hospitalization rates is maintained for at least 10-12 years.
Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I.
The present follow-up is the first heart failure trial where the full life-cycle has been followed from randomization and, after a treatment period of, on average, 6 months, enalapril was shown to be effective.
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.
In patients with asymptomatic left ventricular dysfunction after myocardial infarction, long-term administration of captopril was associated with an improvement in survival and reduced morbidity and mortality due to major cardiovascular events.
The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators.
Treatment with zofenopril significantly improved both short-term and long-term outcome when this drug was started within 24 hours after the onset of acute anterior myocardial infarction and continued for six weeks.
Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial.
It is demonstrated that in patients with anterior MI, the early use of ramipril (titrated to 10 mg) attenuated LV remodeling and was associated with a prompter recovery of LVEF, which supports the results of the major clinical trials, which have demonstrated an early survival benefit of ACE inhibition.
A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.
Long-term treatment with trandolapril in patients with reduced left ventricular function soon after myocardial infarction significantly reduced the risk of overall mortality, mortality from cardiovascular causes, sudden death, and the development of severe heart failure.
The timing of development and subsequent clinical course of heart failure after a myocardial infarction.
The development of HF precedes death in most patients who die in the short- or long-term following an MI and prevention of HF, predominantly by reducing the extent of myocardial damage and recurrent MI, and subsequent management could have a substantial impact on prognosis.